Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoposide Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.83 |
| ▸ | LMNA | P02545 | 6/20 | 0.83 |
| ▸ | GAA | P10253 | 5/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.83 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.83 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.83 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoposide Phosphate SCHEMBL3621 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL1649994 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL15118344 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13524290 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13318053 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL15395274 | 0.96 | CYP3A4 (0.81) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL8727825 | 0.95 | CYP3A4 (0.80) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13318140 | 0.95 | CYP3A4 (0.75) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL13524695 | 0.95 | CYP3A4 (0.75) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13318121 | 0.94 | CYP3A4 (0.74) | CYP3A4LMNAGAASMN1; SMN2TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804601-B1 | PHORBOL ESTER compounds for use in the treatment of neoplastic diseases | BIOSUCCESS BIOTECH CO LTD (US) | 2025-04-02 | — | — | EP | claimed |
| EP-4219492-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2024-11-27 | — | — | EP | claimed |
| EP-3652166-B1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-11-20 | — | — | EP | claimed |
| EP-3720422-B1 | LIPOSOMAL SYSTEM FOR DRUG DELIVERY | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2024-07-17 | — | — | EP | claimed |
| EP-3217983-B1 | ENHANCEMENT OF TUMOR RESPONSE TO CHEMOTHERAPY BY ACTIVATION OF THE ASMASE/CERAMIDE PATHWAY THROUGH TIMED ADMINISTRATION OF A SHORT-ACTING ANTI-ANGIOGENIC AGENT | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-05-01 | — | — | EP | claimed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | claimed |
| EP-3753938-B1 | SUBSTUTUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-03-20 | — | — | EP | claimed |
| EP-3337816-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-02-14 | — | — | EP | claimed |
| EP-3788032-B1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-01-24 | — | — | EP | claimed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | claimed |
| EP-3313443-B9 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | IMMUNOMEDICS INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| EP-3568205-B1 | TREATMENT OF CANCER CELLS OVEREXPRESSING SOMATOSTATIN RECEPTORS USING OCREOTIDE DERIVATIVES CHELATED TO RADIOISOTOPES | RADIOMEDIX INC (US) | 2023-08-16 | — | — | EP | claimed |
| EP-3313443-B1 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | IMMUNOMEDICS INC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3524618-B1 | GLA DOMAINS AS TARGETING AGENTS | GLADIATOR BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | claimed |
| EP-3674302-B1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE HOLDINGS CORP (US) | 2023-03-01 | — | — | EP | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| EP-1981512-B1 | MODIFIED MACROMOLECULE | STARPHARMA PTY LTD (AU) | 2022-11-02 | — | — | EP | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| EP-3801622-B1 | A TOPOISOMERASE INHIBITOR FOR MIMICKING THE EFFECT OF IONIZING RADIATIONS ON T CELLS | NOVAGRAY (FR) | 2022-08-31 | — | — | EP | claimed |